Menu
ÚHKT

Mgr. Hana Remešová, Ph.D.

odborný pracovník v laboratorních metodách

Tel: +420 221 977 231
Email: Hana.Hajkova@uhkt.cz

Pracoviště:

Impaktované publikace

[1]

Curik, N.; Burda, P.; Vargova, K.; Pospisil, V.; Belickova, M.; Vlckova, P.; Savvulidi, F.; Necas, E.; Hajkova, H.; Haskovec, C.; Cermak, J.; Krivjanska, M.; Trneny, M.; Laslo, P.; Jonasova, A.; Stopka, T.

5-Azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity

[rok vydání 2012, impact factor 10.164 ]

[2]

Šestáková, Š.; Cerovská, E.; Cyril Šálek, C.; Kundrát, D.; Ježíšková, I.; Folta, A.; Mayer, J.; Ráčil, Z.; Cetkovský, P.; Remešová, H.

A validation study of potential prognostic DNA methylation biomarkers in patients with acute myeloid leukemia using a custom DNA methylation sequencing panel

[rok vydání 2022, impact factor 6.551 ]

[3]

Merkerova, M.D.; Remesova, H.; Krejcik, Z.; Loudova, N.; Hrustincova, A.; Szikszai, K.; Cermak, J.; Jonasova, A.; Belickova, M.

Relationship between altered miRNA expression and DNA methylation of the DLK1-DIO3 region in azacitidine-treated patients with myelodysplastic syndromes and acute myeloid leukemia with myelodysplasia-related changes

[rok vydání 2018, impact factor 5.656 ]

[4]

Folta, A.; Culen, M.; Jeziskova, I.; Herudkova, Z.; Tom, N.; Hlubinkova, T.; Janeckova, V.; Durinikova, A.; Vydra, J.; Semerad, L.; Dvorakova, D.; Remesova, H.; Cerovska, E.; Cetkovsky, P.; et al.

Prognostic significance of mutation profile at diagnosis and mutation persistence during disease remission in adult acute myeloid leukaemia patients

[rok vydání 2019, impact factor 5.518 ]

[5]

Hájková, H.; Fritz, M.H-Y.; Haškovec, C.; Schwarz, J.; Šálek, C.; Marková, J.; Krejčík, Z.; Dostálová Merkerová, M.; Kostečka, A.; Vostrý, M.; Fuchs, O.; Michalová, K.; Cetkovský, P.; Beneš, V.

CBFB - MYH11 hypomethylation signature and PBX3 differential methylation revealed by targeted bisulfite sequencing in patients with acute myeloid leukemia

[rok vydání 2014, impact factor 4.812 ]

[6]

Dostalova Merkerova, M.; Bystricka, D.; Belickova, M.; Krejcik, Z.; Zemanova, Z.; Polak, J.; Hajkova, H.; Brezinova, J.; Michalova, K.; Cermak, J.

From cryptic chromosomal lesions to pathologically relevant genes: integration of SNP-array with gene expression profiling in myelodysplastic syndrome with normal karyotype

[rok vydání 2011, impact factor 3.546 ]

[7]

Šestáková, Š.; Krejčík, Z.; Folta, A.; Cerovská, E.; Šálek, C.; Dostálová Merkerová, M.; Pecherková, P.; Ráčil, Z.; Mayer, J.; Cetkovský, P.; Remešová, H.

DNA methylation and hydroxymethylation patterns in acute myeloid leukemia patients with mutations in DNMT3A and IDH1/2 and their combinations

[rok vydání 2019, impact factor 3.436 ]

[8]

Šálek, C.; Vydra, J.; Cerovská, E.; Šestáková, Š.; Ransdorfová, Š.; Válková, V.; Cetkovský, P.; Remešová, H.

WT1 expression in peripheral blood at diagnosis and during the course of early consolidation treatment correlates with survival in patients with intermediate and poor-risk acute myeloid leukemia

[rok vydání 2020, impact factor 3.231 ]

[9]

Hájková, H.; Marková, J.; Haškovec, C.; Šárová, I.; Fuchs, O.; Kostečka, A.; Cetkovský, P.; Michalová, K.; Schwarz, J.

Decreased DNA methylation in acute myeloid leukemia patients with DNMT3A mutations and prognostic implications of DNA methylation

[rok vydání 2012, impact factor 2.764 ]

[10]

Šestáková, Š.; Šálek, C.; Remešová, H.

DNA methylation validation methods: a coherent review with practical comparison

[rok vydání 2019, impact factor 2.711 ]

[11]

Jonasova, A.; Bokorova, R.; Polak, J.; Vostry, M.; Kostecka, A.; Hajkova, H.; Neuwirtova, R.; Siskova, M.; Sponerova, D.; Cermak, J.; Mikulenkova, D.; Cervinek, L.; Brezinova, J.; Michalova, K.; Fuchs, O.

High level of full length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide

[rok vydání 2014, impact factor 2.544 ]

[12]

Neuwirtova, R.; Fuchs, O.; Holicka, M.; Vostry, M.; Kostecka, A.; Hajkova, H.; Jonasova, A.; Cermak, J.; Cmejla, R.; Pospisilova, D.; Belickova, M.; Siskova, M.; Hochova, I.; Vondrakova, J.; Sponerova, D.; Kadlckova, E.; Novakova, L.; Brezinova, J.; Michalova, K.

Transcription factors Fli1 and EKLF in the differentiation of megakaryocytic and erythroid progenitor in 5q- syndrome and in Diamond-Blackfan anemia

[rok vydání 2012, impact factor 2.396 ]

[13]

Polák, J.; Hájková, H.; Haškovec, C.; Čechová, H.; Marinov, I.; Mikulenková, D.; Marková, J.; Vítek, A.; Válková, V.

Quantitative monitoring of WT-1 expression in peripheral blood before and after allogenenic stem cell transplantation for acute myeloid leukemia: a useful tool for early detection of minimal residual disease

[rok vydání 2012, impact factor 1.642 ]

[14]

Belickova, M.; Dostalova Merkerova, M.; Votavova, H.; Valka, J.; Vesela, J.; Pejsova, B.; Hajkova, H.; Klema, J.; Cermak, J.; Jonasova, A.

Up-regulation of ribosomal genes is associated with a poor response to azacitidine in myelodysplasia and related neoplasms

[rok vydání 2016, impact factor 1.610 ]

[15]

Válková, V.; Polák, J.; Marková, M.; Vítek, A.; Hájková, H.; Šálek, C.; Procházka, B.; Cetkovský, P.; Trněný, M.

Minimal residual disease detectable by quantitative assessment of WT1 gene before allogeneic stem cell transplantation in patients in first remission of acute myeloid leukemia has an impact on their future prognosis

[rok vydání 2012, impact factor 1.486 ]

[16]

Polák, J.; Hájková, H.; Maaloufová-Soukupová, J.; Marková, J.; Šálek, C.; Schwarz, J.; Haškovec, C.

Estimation of molecular upper remission limit for monitoring minimal residual disease in peripheral blood of acute myeloid leukemia patients by WT1 expression

[rok vydání 2011, impact factor 0.344 ]